Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 2694-2707

  Clutterbuck, Lisa A ^a   Posada, Cristina Garcia ^a   Visintin, Cristina ^a   Riddall, Dieter R ^a   Lancaster, Barrie ^a   Gane, Paul J ^a   Garthwaite, John ^a   Selwood, David L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[5 (1 BENZYL 1H INDAZOL 3 YL) 1,2,4 OXADIAZOL 3 YL]METHANAMINE; [5 (2 BENZYL 2H INDAZOL 3 YL) 1,2,4 OXADIAZOL 3 YL]METHANAMINE; BW 202W92; CFM 1178; CFM 6058; CYTOCHROME P450; INDAZOLE DERIVATIVE; LAMOTRIGINE; NEUROPROTECTIVE AGENT; OXADIAZOLYLINDAZOLE DERIVATIVE; SIPATRIGINE; SODIUM CHANNEL AFFECTING AGENT; TETRODOTOXIN; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL STRAIN HEK293; CHANNEL GATING; CONTROLLED STUDY; DRUG SYNTHESIS; HIPPOCAMPUS; HUMAN; HUMAN CELL; IC 50; NEUROPROTECTION; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; RAT; REACTION ANALYSIS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; ELECTROPHYSIOLOGICAL PROCESSES; HIPPOCAMPUS; INDAZOLES; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN ISOFORMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, WISTAR; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 65649146047     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801180p     Document Type: Article

References (60)

1. Catterall, W. A. Structure and function of voltage-gated ion channels. Annu. Rev. Biochem. 1995, 64, 493-531.
2. Catterall, W. A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000, 26, 13-25.
3. Tarnawa, I.; Bolcskei, H.; Kocsis, P. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases. Recent Pat. CNS Drug Discovery 2007, 2, 57-78. (Pubitemid 46729091)
4. Clare, J. J.; Tate, S. N.; Nobbs, M.; Romanos, M. A. Voltage-gated sodium channels as therapeutic targets. Drug Discovery Today 2000, 5, 506-520.
5. Perucca, E.; French, J.; Bialer, M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007, 9, 793-804. (Pubitemid 47243712)
6. Choi, H.; Morrell, M. J. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin. Pharmacother. 2003, 4, 243-251. (Pubitemid 36240464)
7. Ambrosio, A. F.; Soares-Da-Silva, P.; Carvalho, C. M.; Carvalho, A. P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 2002, 27, 121-130. (Pubitemid 34242438)
8. Wood, J. N.; Boorman, J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr. Top. Med. Chem. 2005, 5, 529-537. (Pubitemid 41052325)
9. Baker, M. D.; Wood, J. N. Involvement of Na+ channels in pain pathways. Trends Pharmacol. Sci. 2001, 22, 27-31. (Pubitemid 32126283)
10. Lai, J.; Hunter, J. C.; Porreca, F. The role of voltage-gated sodium channels in neuropathic pain. Curr. Opin. Neurobiol. 2003, 13, 291-297. (Pubitemid 36792241)
11. Amir, R.; Argoff, C. E.; Bennett, G. J.; Cummins, T. R.; Durieux, M. E.; Gerner, P.; Gold, M. S.; Porreca, F.; Strichartz, G. R. The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain 2006, 7, S1-S29.
12. Sindrup, S. H.; Jensen, T. S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83, 389-400.
13. Backonja, M. Anticonvulsants for the treatment of neuropathic pain syndromes. Curr. Pain Headache Rep. 2003, 7, 39-42. (Pubitemid 38915068)
14. Jensen, T. S. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur. J. Pain 2002, 6, 61-68.
15. Veneroni, O.; Maj, R.; Calabresi, M.; Faravelli, L.; Fariello, R. G.; Salvati, P. Anti-allodynic effect of NW-1029, a novel Na(+) channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain 2003, 102, 17-25. (Pubitemid 36298858)
16. Mao, J.; Chen, L. L. Systemic lidocaine for neuropathic pain relief. Pain 2000, 87, 7-17. (Pubitemid 30345657)
17. Kyle, D. J.; Ilyin, V. I. Sodium channel blockers. J. Med. Chem. 2007, 50, 2583-2588. (Pubitemid 46896063)
18. Nassar, M. A.; Baker, M. D.; Levato, A.; Ingram, R.; Mallucci, G.; McMahon, S. B.; Wood, J. N. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol. Pain 2006, 2, 33.
19. Waxman, S. G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosisscurrent status. Nat Clin. Pract. Neurol. 2008, 4, 159-169.
20. Tymianski, M.; Tator, C. H. Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery 1996, 38, 1176-1195. (Pubitemid 26162765)
21. Wolf, P. A.; Cobb, J. L.; D'Agostino, R. B. Stroke Pathophysiology, Diagnosis, and Management; W.B. Saunders: Philadelphia, PA, 1998.
22. Green, A. R.; Shuaib, A. Therapeutic strategies for the treatment of stroke. Drug Discovery Today 2006, 11, 681-693. (Pubitemid 44056287)
23. Squire, I. B.; Lees, K. R.; Pryse-Phillips, W.; Kertesz, A.; Bamford, J. Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group. Ann. N.Y. Acad. Sci. 1995, 765, 317-318. (Pubitemid 26136267)
24. Diener, H. C.; Hacke, W.; Hennerici, M.; Radberg, J.; Hantson, L.; De, K. J. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group. Stroke 1996, 27, 76-81.
25. Muir, K. W.; Holzapfel, L.; Lees, K. R. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc. Dis. 2000, 10, 431-436.
26. Cheng, Y. D.; Al-Khoury, L.; Zivin, J. A. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004, 1, 36-45. (Pubitemid 46589340)
27. De, K. J.; Sulter, G.; Luiten, P. G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 1999, 22, 535-540.
28. Bensimon, G.; Doble, A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin. Drug Saf. 2004, 3, 525-534. (Pubitemid 39530206)
29. Stocchi, F.; Arnold, G.; Onofrj, M.; Kwiecinski, H.; Szczudlik, A.; Thomas, A.; Bonuccelli, U.; Van, D. A.; Cattaneo, C.; Sala, P.; Fariello, R. G. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004, 63, 746-748. (Pubitemid 39100843)
30. Kapoor, R. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol. Sci. 2008, 274, 54-56.
31. Garthwaite, G.; Goodwin, D. A.; Neale, S.; Riddall, D.; Garthwaite, J. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition. Mol. Pharmacol. 2002, 61, 97-104. (Pubitemid 34049516)
32. Waxman, S. G. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat. Rev. Neurosci. 2006, 7, 932-941.
33. Anger, T.; Madge, D. J.; Mulla, M.; Riddall, D. Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J. Med. Chem. 2001, 44, 115-137. (Pubitemid 32096657)
34. Unverferth, K.; Engel, J.; Hofgen, N.; Rostock, A.; Gunther, R.; Lankau, H. J.; Menzer, M.; Rolfs, A.; Liebscher, J.; Muller, B.; Hofmann, H. J. Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles. J. Med. Chem. 1998, 41, 63-73. (Pubitemid 28070468)
35. Lankau, H. J.; Unverferth, K.; Grunwald, C.; Hartenhauer, H.; Heinecke, K.; Bernoster, K.; Dost, R.; Egerland, U.; Rundfeldt, C. New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity. Eur. J. Med. Chem. 2007, 42, 873-879. (Pubitemid 46824015)
36. Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today 2003, 8, 86-96. (Pubitemid 36139902)
37. Selwood, D. L.; Brummell, D. G.; Budworth, J.; Burtin, G. E.; Campbell, R. O.; Chana, S. S.; Charles, I. G.; Fernandez, P. A.; Glen, R. C.; Goggin, M. C.; Hobbs, A. J.; Kling, M. R.; Liu, Q.; Madge, D. J.; Meillerais, S.; Powell, K. L.; Reynolds, K.; Spacey, G. D.; Stables, J. N.; Tatlock, M. A.; Wheeler, K. A.; Wishart, G.; Woo, C. K. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J. Med. Chem. 2001, 44, 78-93. (Pubitemid 32049785)
38. Lu, J. J.; Crimin, K.; Goodwin, J. T.; Crivori, P.; Orrenius, C.; Xing, L.; Tandler, P. J.; Vidmar, T. J.; Amore, B. M.; Wilson, A. G.; Stouten, P. F.; Burton, P. S. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J. Med. Chem. 2004, 47, 6104-6107. (Pubitemid 39507351)
39. Kayukova, L. Synthesis of 1,2,4-oxadiazoles (a review). Pharm. Chem. J. 2005, 39, 539-547.
40. Sureshbabu, V. V.; Hemantha, H. P.; Naik, S. A. Synthesis of 1,2,4-oxadiazole-linked orthogonally urethane-protected dipeptide mimetics. Tetrahedron Lett. 2008, 49, 5133-5136.
41. Santagada, V.; Frecentese, F.; Perissutti, E.; Cirillo, D.; Terracciano, S.; Caliendo, G. A suitable 1,2,4-oxadiazoles synthesis by microwave irradiation. Bioorg. Med. Chem. Lett. 2004, 14, 4491-4493 (Pubitemid 39043971)
42. Evans, M. D.; Ring, J.; Schoen, A.; Bell, A.; Edwards, P.; Berthelot, D.; Nicewonger, R.; Baldino, C. M. The accelerated development of an optimized synthesis of 1,2,4-oxadiazoles: application of microwave irradiation and statistical design of experiments. Tetrahedron Lett. 2003, 44, 9337-9341. (Pubitemid 37485831)
43. Tsunoda, T.; Otsuka, J.; Yamamiya, Y.; Itô, S. N,N,N′, N′;-Tetramethylazodicarboxamide (TMAD), a new versatile reagent for Mitsunobu reaction. Its application to synthesis of secondary amines. Chem. Lett. 1994, 23, 539-542.
44. Pauwels, P. J.; Leysen, J. E.; Laduron, P. M. [3H]Batrachotoxinin A 20-alpha-benzoate binding to sodium channels in rat brain: characterization and pharmacological significance. Eur. J. Pharmacol. 1986, 124, 291-298. (Pubitemid 16056720)
45. Riddall, D. R.; Leach, M. J.; Garthwaite, J. A novel drug binding site on voltage-gated sodium channels in rat brain. Mol. Pharmacol. 2006, 69, 278-287. (Pubitemid 43048914)
46. + flux and the anoxic depolarization to adenosine 5′-triphosphate levels in hypoxic/hypoglycemic rat hippocampal slices. Neuroscience 1998, 83, 717-722.
47. Lin, A. QuaSAR-Descriptor, Molecular Operating Envirionment. http://www.chempcomp.com, 2007.
48. Trezise, D. J.; John, V. H.; Xie, X. M. Voltage- and use-dependent inhibition of Na+ channels in rat sensory neurones by 4030W92, a new antihyperalgesic agent. Br. J. Pharmacol. 1998, 124, 953-963. (Pubitemid 28312830)
49. + channels. Neuroscience 1996, 73, 951-962.
50. + channels and with native Na+ channels in rat hippocampal neurones. Pfluegers Arch. 1995, 430, 437-446.
51. Jarnot, M.; Corbett, A. M. Immunolocalization of NaV1.2 channel subtypes in rat and cat brain and spinal cord with high affinity antibodies. Brain Res. 2006, 1107, 1-12. (Pubitemid 44205114)
52. Blumenfeld, H.; Lampert, A.; Klein, J. P.; Mission, J.; Chen, M. C.; Rivera, M.; Dib-Hajj, S.; Brennan, A. R.; Hains, B. C.; Waxman, S. G. Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis. Epilepsia 2008, 50, 44-55.
53. Lindia, J. A.; Abbadie, C. Distribution of the voltage gated sodium channel Na(v)1.3-like immunoreactivity in the adult rat central nervous system. Brain Res. 2003, 960, 132-141. (Pubitemid 36044569)
54. Guo, F.; Yu, N.; Cai, J. Q.; Quinn, T.; Zong, Z. H.; Zeng, Y. J.; Hao, L. Y. Voltage-gated sodium channel Nav1.1, Nav1.3 and beta1 subunit were up-regulated in the hippocampus of spontaneously epileptic rat. Brain Res. Bull. 2008, 75, 179-187.
55. Drizin, I.; Gregg, R. J.; Scanio, M. J. C.; Shi, L.; Gross, M. F.; Atkinson, R. N.; Thomas, J. B.; Johnson, M. S.; Carroll, W. A.; Marron, B. E.; Chapman, M. L.; Liu, D.; Krambis, M. J.; Shieh, C. C.; Zhang, X.; Hernandez, G.; Gauvin, D. M.; Mikusa, J. P.; Zhu, C. Z.; Joshi, S.; Honore, P.; Marsh, K. C.; Roeloffs, R.; Werness, S.; Krafte, D. S.; Jarvis, M. F.; Faltynek, C. R.; Kort, M. E. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg. Med. Chem. 2008, 16, 6379-6386.
56. Fraser, R. A.; Sherrington, R.; Macdonald, M. L.; Samuels, M.; Newman, S.; Fu, J. M.; Kamboj, R. Potent and Selective Nav1.7 Sodium Channel Blockers. PCT/US2007/00725 [WO/2007/109324], 2007.
57. Hains, B. C.; Saab, C. Y.; Waxman, S. G. Changes in electrophysiological properties and sodium channel Nav1.3 expression in thalamic neurons after spinal cord injury. Brain 2005, 128, 2359-2371. (Pubitemid 41407975)
58. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K.; Gaman, E. A.; Houston, J. B.; Tremaine, L. M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 2006, 316, 336-348. (Pubitemid 41832613)
59. Benet, L. Z.; Kroetz, D. L.; Sheiner, L. B. Pharmacokinetics: The Dynamics of Drug Absorption Distribution and Elimination. In Goodman & Gilman's The Pharmacological Basis of Therapeutics; McGraw-Hill, Health Professions Division: New York, 1996; pp 3-27.
60. Scheuer, T.; Catterall, W. A. Control of neuronal excitability by phosphorylation and dephosphorylation of sodium channels. Biochem. Soc. Trans. 2006, 34, 1299-1302. (Pubitemid 46769042)